What is QNTM's earnings growth forecast for 2025-2025?
(NASDAQ: QNTM) Quantum Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 80.88%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 71.14%.
Quantum Biopharma's earnings in 2025 is -$9,863,002.
In 2025, QNTM is forecast to generate -$3,541,233 in earnings, with the lowest earnings forecast at -$3,541,233 and the highest earnings forecast at -$3,541,233.
What is QNTM's revenue growth forecast for 2026-2026?
(NASDAQ: QNTM) Quantum Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 3.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 59.56%.
Quantum Biopharma's revenue in 2025 is $0.
In 2026, QNTM is forecast to generate $34,377,555 in revenue, with the lowest revenue forecast at $34,377,555 and the highest revenue forecast at $34,377,555.
What is QNTM's forecast return on assets (ROA) for 2025-2026?
(NASDAQ: QNTM) forecast ROA is -5.8%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 12.71%.
What is QNTM's Earnings Per Share (EPS) forecast for 2025-2025?
(NASDAQ: QNTM) Quantum Biopharma's current Earnings Per Share (EPS) is -$9.11. In 2025, QNTM's EPS is forecast to hit -$1.54 (min: -$1.54, max: -$1.54).
What is QNTM's forecast return on equity (ROE) for 2025-2026?
(NASDAQ: QNTM) forecast ROE is -8.65%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.